103416-88-2

Basic information

• Product Name: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-hydroxyphenyl)-5-methyl-
• CAS NO: 103416-88-2
• Molecular Formula: C11H12N2O2
• Molecular Weight: 204.228
• Mol File: 103416-88-2.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-hydroxyphenyl)-5-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-hydroxyphenyl)-5-methyl-(103416-88-2)
• EPA Substance Registry System: 3(2H)-Pyridazinone, 4,5-dihydro-6-(4-hydroxyphenyl)-5-methyl-(103416-88-2)

Safety Data

• Hazardous Substances Data: 103416-88-2(Hazardous Substances Data)

Upstream product

• 36725-28-7 6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone 
• 67-63-0 isopropyl alcohol 
• 539820-72-9 ethyl 2-ethoxycarbonyl-3-(4-methoxybenzoyl)butanoate 
• 121-97-1 4-Methoxypropiophenone 
• 5717-17-9 3-(4'-methoxybenzoyl)-3-methylpropionic acid 
• 21086-33-9 2-bromo-1-(4-methoxyphenyl)-1-propanone 
• 539820-74-1 6-(4-methoxyphenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one 

Downstream Products

• 1010801-47-4 C₂₉H₃₄N₆O₄ 
• 1010801-69-0 C₃₀H₃₃F₃N₆O₄ 
• 1010801-67-8 C₂₉H₃₁F₃N₆O₄ 
• 1010801-65-6 C₂₈H₂₉F₃N₆O₄ 
• 1060640-71-2 C₃₀H₃₆N₆O₄ 
• 1010801-57-6 C₂₉H₃₂N₆O₄ 
• 1010801-53-2 C₂₉H₃₄N₆O₄ 
• 1010801-49-6 C₃₀H₃₆N₆O₄ 
• 1093857-23-8 5-(8-methoxy-2-methylquinolin-5-yl)-2-[4-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenoxy]lbutyl]-4,4-dimethyl-4,4-dihydro-pyrazol-3-one 
• 1010801-13-4 6-(4-(2-((tert-butyldiphenylsilyl)oxy)ethoxy)phenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one 
• 1094101-95-7 6-(8-Methoxy-2-methylquinolin-5-yl)-5-methyl-2-[4-[4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenoxy]butyl]-4,5-dihydro-2H-pyridazin-3-one 
• 141775-65-7 6-[4-(3-hydroxypropyloxy)phenyl]-5-methyl-4,5-dihydro-3 (2H)-pyridazinone 
• 134678-46-9 (+)-6-(4'-butanoyloxyphenyl)-4,5-dihydro-5S-methyl-3(2H)-pyridazinone 

Relevant articles and documents

A kind of levosimendan impurity and its preparation and detection method

The invention discloses a levosimendan impurity, and the impurity is produced in diazotization and condensation reaction in the presence of alcohol (such as ethanol), water and other nucleophiles in the synthesis process of levosimendan. The invention also provides a preparation method of the impurity, the preparation method comprises the steps of preparation of formula III compound by diazotization from 6-(4-amino phenyl)-4, 5-dihydro-5-methyl-3 (2H) - pyridazinone, and preparation of the impurity by reaction of the formula III compound and TOH. The invention also provides a detection method of the impurity and application of the impurity in the study of the quality of levosimendan pharmaceutical raw materials and preparations.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

Pyridazinones having cardiotonic and beta blocking activities

Pyridazinones of the following formula (I): STR1 where R1 -R4 are a variety of substituents and L is a linking group, a pharmaceutical composition for treating congestive heart failure, novel intermediates, methods for such treatment and processes for preparing compounds of formula (I).